Skip to main content
Clinical Trials/NCT00599118
NCT00599118
Active, not recruiting
Not Applicable

Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

The Cleveland Clinic1 site in 1 country1,300 target enrollmentAugust 1, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
The Cleveland Clinic
Enrollment
1300
Locations
1
Primary Endpoint
Genetic variants associated with atrial fibrillation
Status
Active, not recruiting
Last Updated
7 months ago

Overview

Brief Summary

The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

Detailed Description

Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.

Registry
clinicaltrials.gov
Start Date
August 1, 2005
End Date
December 1, 2035
Last Updated
7 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mina Chung, MD

Principal Investigator

The Cleveland Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Genetic variants associated with atrial fibrillation

Time Frame: Baseline

Genome-wide association study of atrial fibrillation

Study Sites (1)

Loading locations...

Similar Trials